[Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
Zhonghua Gan Zang Bing Za Zhi
; 29(4): 326-331, 2021 Apr 20.
Article
in Zh
| MEDLINE
| ID: mdl-33979958
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Observational_studies
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Gan Zang Bing Za Zhi
Journal subject:
GASTROENTEROLOGIA
Year:
2021
Document type:
Article
Affiliation country:
China